Stock Chart

SLS

$4.06 +2.14%
Score: 54.3 HOLD
LEAPs: SELL $7
i
LEAPs Option Signal

Type: SELL wallstreet
Strike: $7
Premium: $1.70
Expiry: Jan 15, 2027
Target: $7
Score: -100

LEAPs are long-term options (1+ year) with less time decay.
30D Target: $3.11 - $4.05 STRONG_UPTREND
i
30D Trendline Target

This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.

How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future

Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling

⚠️ Not a prediction. Shows trend projection only.

R-squared: 0.59
Vol: 0.16x (vs SPY: 0.4x | vs QQQ: 0.3x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About SLS - SELLAS Life Sciences Group, Inc. Common Stock

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Key Statistics

Market Cap $642M

This SLS stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track SLS's price movements with trendlines, gamma walls, and key support/resistance levels.